⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Reaching your target weight on a GLP-1 medication is a significant achievement. But for many Indian patients, a new set of questions emerges: Can I stop the medication now? Will the weight come back? How do I maintain what I have achieved? What changes at this point?
This guide addresses the maintenance phase of GLP-1 therapy — the period after you have reached your goal — and explains your options clearly in the Indian medical and economic context.
Consult your healthcare provider before starting any medication, stopping it, or making changes to your dosage or treatment plan.
The most important thing to understand is this: GLP-1 medications treat a chronic condition — obesity or type 2 diabetes — in the same way that blood pressure medications treat hypertension. When you stop the medication, the underlying biological drivers of weight gain (hormonal dysregulation, increased appetite, reduced satiety signalling) return.
Clinical evidence from the STEP 1 Extension trial showed that participants who stopped semaglutide 2.4 mg regained approximately two-thirds of their lost weight within 12 months of stopping. Similarly, data from the SURMOUNT-5 program on tirzepatide showed substantial weight regain after discontinuation.
This does not mean maintenance is impossible. It means the strategy for maintenance depends on whether you continue medication, and at what dose.
This is the approach recommended in international clinical guidelines and supported by the strongest evidence. After reaching your target weight, your doctor may reduce your dose to the minimum effective maintenance dose — typically the lowest dose that prevents weight regain.
For semaglutide, this is often 0.5 mg or 1 mg weekly (rather than the weight loss dose of 2 mg). For tirzepatide, some patients maintain at 5 mg after losing weight at 10 mg or 15 mg.
Advantages: Best weight maintenance outcomes; continued metabolic benefits (blood sugar control, cardiovascular protection)
Disadvantage: Ongoing cost (approximately Rs 6,000–14,000 per month for lower-dose semaglutide)
This is possible for a minority of patients — particularly those who have made substantial, sustainable lifestyle changes, are at a body weight they can maintain with diet and exercise alone, and have resolved the underlying metabolic condition (for example, achieved remission of type 2 diabetes).
The honest reality: most patients who stop GLP-1 medications without continuation do experience some weight regain. The success rate for maintaining significant (10%+) weight loss purely through lifestyle is 15–20% at five years in the general population.
Who this works best for: Younger patients who have lost weight primarily through dietary changes, have established strong exercise habits, have no ongoing metabolic conditions requiring treatment.
Some patients choose to reduce to a lower maintenance dose and step back up if weight regain exceeds 5%. This requires close monitoring and an honest conversation with your prescribing doctor about what triggers a return to the full dose.
Work with your doctor to define a maintenance range rather than a single target number — for example, "between 72 and 76 kg." A 3–4 kg range acknowledges normal fluctuation from fluid, food, and hormonal cycles.
Weigh yourself once weekly, at the same time of day (morning, before eating). Do not weigh daily — it creates unnecessary anxiety over normal fluctuations.
During weight loss, the priority was calorie restriction supported by medication-suppressed appetite. During maintenance, the priority shifts:
Exercise does not produce significant weight loss on its own, but it is the strongest predictor of long-term weight maintenance. Specifically:
In the Indian context, yoga with strength elements (surya namaskar, ashtanga) counts as both resistance and aerobic exercise. Functional bodyweight training is effective and does not require a gym.
Once you reach maintenance, your doctor should reassess which blood tests are still needed and at what frequency. Typical monitoring on maintenance therapy includes:
The most common reason for weight regain during maintenance is a gradual drift back to prior eating patterns — not a single event, but a slow accumulation of "just this once" decisions. Warning signs:
None of these are moral failures — they are normal human responses. The maintenance plan should include a pre-agreed trigger point (for example: "if I gain 4 kg above my maintenance weight, I will return to my prescribing doctor to reassess").
Indian households often involve shared cooking, and the family diet naturally reverts over time. A few strategies for navigating this:
At festivals and celebrations: The Indian calendar is full of opportunities for calorie-dense eating. A useful rule: enjoy the celebration within the meal, and do not extend it for the next 3 days. One plate of Diwali sweets at the family gathering is fine; a week of mithai left on the kitchen counter is a maintenance challenge.
With family pressure: "Tu abhi bhi khate nahi ho?" (You still don't eat?) is common from well-meaning relatives. A simple response: "Main khana kha raha/rahi hun, bas thoda zyada dhyan de raha/rahi hun." (I am eating, just being a little more mindful.)
When cooking for others: Cook the high-protein, lower-oil versions of dishes for yourself while everyone else eats the full versions. In practice, these adapted versions are often preferred by the whole family over time.
Weight regain during the maintenance phase is not a failure — it is a signal that the current strategy needs adjustment. The response depends on the extent of regain:
GLP-1 medications manage obesity and metabolic disease. There is no shame in needing long-term or permanent medication for a chronic condition.
The cost of long-term GLP-1 therapy is a real consideration for Indian patients. At maintenance doses, approximate monthly costs:
| Medication | Maintenance Dose | Approx. Monthly Cost (India, 2025) |
|---|---|---|
| Semaglutide (Ozempic) | 0.5 mg/week | Rs 8,000–10,000 |
| Semaglutide (Ozempic) | 1 mg/week | Rs 10,000–14,000 |
| Rybelsus (oral) | 7 mg/day | Rs 5,000–8,000 |
| Tirzepatide (Mounjaro) | 5 mg/week | Rs 15,000–20,000 |
Discuss with your doctor whether Rybelsus (oral semaglutide) is an appropriate option for maintenance — it is generally the lowest-cost semaglutide formulation available in India and may be sufficient at maintenance doses.
Q: Can I stop Ozempic or Mounjaro now that I have reached my target weight? A: Stopping is possible, but be prepared for likely weight regain. Discuss the risks and your options with your doctor. Most evidence supports continuing at a lower maintenance dose for better long-term outcomes.
Q: I have been on Ozempic for weight loss only (no diabetes). Should I continue? A: This depends on your individual situation. For pure weight loss without metabolic comorbidities, some patients successfully maintain with lifestyle after stopping. However, most will regain weight. Discuss your specific risk factors, metabolic health markers, and the cost-benefit balance with your doctor.
Q: I feel fine without the medication. Why does the literature say weight returns? A: GLP-1 medications work partly by suppressing hunger hormones (particularly ghrelin) and enhancing satiety signalling. When the medication stops, these hormonal drivers of weight gain return. You may not immediately notice increased hunger, but over weeks and months, calorie intake tends to gradually increase. This is biology, not willpower.
Q: What is the lowest effective dose of semaglutide for maintenance in India? A: There is no universal answer — it varies by individual. Some patients maintain well at 0.5 mg; others need 1 mg. Your prescribing doctor should assess this based on your weight trends over 2–3 months at the lower dose.
